Listing Of MNC Arms In India Has Been Rough Ride With Stray Sparks Of Hope
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As Pfizer Inc. looks to potentially spin-off its emerging markets unit and analysts talk openly about spin-outs for other companies as well, industry watchers may want to take a closer look at India, where several Big Pharma have had separately listed subsidiaries for decades
You may also be interested in...
AstraZeneca Restores Supply Of Key Recalled Products In India; Plans To Outsource Manufacturing And Launch More Drugs
After being battered by a government probe and voluntary recalls earlier this year, the company appears to be gearing up for a stronger presence in India.
Are Emerging Markets Part Of Big Pharma's Core Business?
As Big Pharma companies increasingly look to emerging markets to capture some of the growth lost from the patent cliff in the U.S. and Europe, they are also shifting focus more to branded generics, leaving some investors to question whether companies would be better off spinning out their emerging market units, which would leave behind smaller companies focused on the core business of developing and marketing innovative therapies
Are Emerging Markets Part Of Big Pharma's Core Business?
As Big Pharma companies increasingly look to emerging markets to capture some of the growth lost from the patent cliff in the U.S. and Europe, they are also shifting focus more to branded generics, leaving some investors to question whether companies would be better off spinning out their emerging market units, which would leave behind smaller companies focused on the core business of developing and marketing innovative therapies